Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

{{::item.ticker}} • {{::item.company_name}} No Results

Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

News & Research
Portfolio
Discover
Groups
$ABBV {{ '2017-07-21T16:09:32+0000' | timeago}} • Announcement

$ABBV received positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for Humira (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients. Uveitis is an inflammation of the uvea, which includes the iris, choroid, and the ciliary body in eye.

$ABBV {{ '2018-01-29T15:39:15+0000' | timeago}} • Webcast

$ABBV expects 1Q18 adjusted EPS of $1.77-1.79 excluding about $0.31 as specified items. $ABBV anticipates 1Q18 operational revenue growth approaching the mid-teens. Holding exchange rates constant at current levels, the company would expect foreign exchange to have a favorable impact on reported sales growth of 3% in 1Q18.

$ABBV {{ '2018-01-29T15:35:39+0000' | timeago}} • Webcast

On the topline in 2018, $ABBV expects revenue approaching $32Bil, which reflects favorable impact from foreign currency of roughly 1.5%. Included in this are the assumptions for the company's key products. Humira will maintain its strong position as the front-line therapy across therapeutic segments and continues to be an important growth driver.

$ABBV {{ '2018-01-29T15:26:22+0000' | timeago}} • Webcast

$ABBV's ongoing Phase 3 studies in small-cell lung cancer also continue to advance, with the Tahoe study in second-line setting and the Meru trial in front-line patients both now well underway. $ABBV is also evaluating Rova-T with Opdivo and with Opdivo and Yervoy in mid-stage combination study with potential to start seeing data later in the year.

$ABBV {{ '2018-01-29T15:23:26+0000' | timeago}} • Webcast

This year, $ABBV will launch major label expansion for Vebclexta in relapsed/refractory cancer type chronic lymphocytic leukemia as well as elagolix in endometriosis. Endometriosis is painful disorder in which tissue that normally lines inside of uterus grows outside.

$ABBV {{ '2018-01-29T15:14:01+0000' | timeago}} • Webcast

In 2018, $ABBV plans to accelerate pension funding by $750MM as well as enhancing non-executive employee compensation. $ABBV is also planning one-time shareable contribution of about $350MM to select not-for-profit organizations, supporting initiatives such as the Puerto Rico rebuilding efforts, children's healthcare access programs, and charities.

$ABBV {{ '2018-01-26T15:15:38+0000' | timeago}} • Announcement

Over next 5 years, $ABBV plans to invest about $2.5Bil in capital projects in the U.S. and the company is currently evaluating additional expansion of its U.S. facilities. The company also plans to accelerate pension funding by $750MM, as well as enhance non-executive employee compensation.

$ABBV {{ '2018-01-26T15:12:51+0000' | timeago}} • Announcement

$ABBV expects FY18 EPS of $6.45-6.55. The company lifted its 2018 adjusted EPS guidance to $7.33-7.43 from $6.37-6.57, to reflect the impact of U.S. tax reform and stronger operating performance. $ABBV sees adjusted effective tax rate to increase to 13% over next 5 years as a result of increased domestic income and investment.

$ABBV {{ '2018-01-26T15:01:09+0000' | timeago}} • Announcement

$ABBV reported a drop in 4Q17 earnings due to about $4.5Bil of tax charge arising from enactment of the Tax Cuts and Jobs Act. Net income fell to $52MM or $0.03 per share from $1.4Bil or $0.85 per share last year. Net revenue grew 14% to $7.74Bil. Adjusted EPS increased 23.3% to $1.48.

$ABBV {{ '2018-01-26T14:34:56+0000' | timeago}} • Infographic

$ABBV AbbVie Inc. Earnings AlphaGraphic: Q4 2017 Highlights

$ABBV {{ '2017-12-21T13:23:43+0000' | timeago}} • Announcement

$ABBV announced positive top-line results from the Phase 3 SELECT-MONOTHERAPY clinical trial. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.

$ABBV {{ '2017-12-04T15:31:15+0000' | timeago}} • Announcement

$ABBV announced that Risankizumab met all co-primary and ranked secondary endpoints in Phase 3 study. Risankizumab is used in the treatment of patients with moderate to severe plaque psoriasis.

$ENTA {{ '2017-11-20T21:52:37+0000' | timeago}} • Announcement

Biotech company $ENTA swung to 4Q17 profit on higher revenue, driven by milestone payments totaling $65MM received following $ABBV's U.S. approval of MAVYRET and EU approval of MAVIRET. Net income was $36.5MM or $1.86 per share in the quarter compared to a net loss of $1.8MM, or $0.09 loss per share a year earlier. Revenue jumped to $75.9MM.

$ABBV {{ '2017-10-27T19:44:43+0000' | timeago}} • Webcast

As $ABBV posted 3Q17 results, it now sees full-year gross margin as a percentage of sales at 80.5% and operating margin at 42.5%. AbbVie also expects full-year net interest expense of approximately $1Bil with an adjusted tax rate of about 19%.

$ABBV {{ '2017-10-27T16:20:17+0000' | timeago}} • Infographic

$ABBV AbbVie, Inc. Earnings AlphaGraphic: Q3 2017 highlights

$ABBV {{ '2017-10-27T12:14:02+0000' | timeago}} • Announcement

$ABBV, as it posted 3Q17 results, declared an 11% hike in the quarterly cash dividend to $0.71 per share, beginning with the dividend payable on Feb. 15, 2018 to shareholders of record as of Jan. 12, 2018.

$ABBV {{ '2017-10-27T12:12:54+0000' | timeago}} • Announcement

As $ABBV posted 3Q17 results, it updated its GAAP diluted EPS guidance for FY17 to $4.27-4.29. AbbVie now expects to deliver adjusted diluted EPS for the full year of $5.53-5.55. The drug giant now sees global HUMIRA sales to approach $21Bil in 2020.

$ABBV {{ '2017-10-27T12:11:23+0000' | timeago}} • Announcement

With worldwide net revenues jumping 8.8% to about $7.0Bil in 3Q17, $ABBV saw net earnings inch up 2% to $1.6Bil or $1.01 per diluted share. Global HUMIRA sales saw a 15% hike while global IMBRUVICA net revenues surged 37% in the quarter.

$ABBV {{ '2017-10-18T16:05:30+0000' | timeago}} • Announcement

$ABBV and Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting biologic therapies, announced that they have entered an immuno-oncology research collaboration.

$ABBV {{ '2017-09-27T12:14:25+0000' | timeago}} • Announcement

$ABBV announced that the Japanese Ministry of Health, Labor and Welfare has approved MAVIRET, a once-daily, treatment for adults with chronic hepatitis C virus infection. The treatment was also recently granted marketing authorization by the European Commission and approved by the US FDA.

$ABBV {{ '2017-09-22T11:48:04+0000' | timeago}} • Announcement

$ABBV and $BMY announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).

Recent Transcripts
SYN | Earnings
February 22nd 2018, 1:30pm
TXMD | Earnings
February 20th 2018, 9:30pm
MDT | Earnings
February 20th 2018, 1:00pm
ACOR | Earnings
February 15th 2018, 1:30pm
AlphaGraphics you may like
Related Feed
Recent Transcripts
SYN | Earnings
February 22nd 2018, 1:30pm
TXMD | Earnings
February 20th 2018, 9:30pm
MDT | Earnings
February 20th 2018, 1:00pm
ACOR | Earnings
February 15th 2018, 1:30pm
AlphaGraphics you may like